Which joints can ChondroFiller treat?

ChondroFiller can be placed in joints beyond the knee — and in clinical practice it has been used in the hip, ankle, wrist, shoulder, and elbow — but the published evidence supporting those applications is not equal across the board.

The hip stands on the firmest ground: a prospective cohort study followed patients for up to five years after treatment of acetabular cartilage lesions, providing the only peer-reviewed, product-specific data in a non-knee joint. The ankle and wrist carry biological rationale and early feasibility findings. The shoulder sits at the exploratory end of the spectrum, with no independent peer-reviewed series yet available.

One principle runs across all of these joints: ChondroFiller's collagen scaffold works by drawing the body's own repair cells into the defect — a mechanism that is not, in theory, limited to the knee. Equally, the core contraindication transfers wherever the scaffold is placed: established osteoarthritis predicts poor outcomes, while focal defects in otherwise preserved joints offer the best prospect of benefit.

The sections below move from the best-supported evidence to the least.

Hip cartilage defects: what the published evidence shows

Published in the Journal of Hip Preservation Surgery, a 2021 prospective cohort is currently the only peer-reviewed, product-specific study of ChondroFiller in a non-knee joint. Of the 26 patients treated for focal acetabular cartilage lesions greater than 2 cm², 21 completed follow-up assessments at three to five years — and 17 of those 21 reported good or excellent outcomes. That amounts to roughly four in five evaluable patients achieving a meaningful improvement in pain and function over the follow-up window.

The study's most important finding for anyone self-screening is not the positive result but the group that did poorly. Patients with established hip osteoarthritis — rated Tönnis grade 2 or 3 on imaging — fared consistently badly. The Tönnis scale is a radiographic measure of hip OA severity; grades 2 and 3 indicate moderate to severe structural joint change. Where those changes are already present, evidence suggests ChondroFiller does not offer meaningful benefit. This mirrors the contraindication pattern documented in the knee literature and reinforces the principle that the scaffold is designed for focal defects within an otherwise preserved joint, not for widespread cartilage loss.

In patients who did respond, reported outcome scores improved in a manner consistent with the approximately 30-point gains recorded in the knee evidence base — suggesting the scaffold's endogenous cell-recruitment mechanism functions in the hip environment in a broadly comparable way.

The sample of 26 patients is small, and these findings should be interpreted with appropriate caution: they indicate a promising direction rather than a settled conclusion. Image-guided scaffold placement in the hip also demands careful pre-procedural assessment, since the joint's anatomy and the degree of existing OA are both critical to patient selection. A detailed review of imaging and clinical history is the starting point for determining suitability.

Ankle cartilage lesions: biological rationale without clinical proof

No peer-reviewed clinical trial or published cohort study has examined ChondroFiller specifically in osteochondral lesions of the talus — the term for a cartilage or bone-cartilage defect inside the ankle joint. That gap deserves straightforward acknowledgement before considering the ankle as a candidate site.

A supporting biological rationale does exist, however. Injectable and membrane-based scaffolds have been studied for ankle OLTs in the broader cartilage repair literature, with multi-year follow-up data demonstrating their feasibility in this joint. ChondroFiller's mechanism — drawing the body's own repair cells into a structured collagen matrix — is not ankle-specific in principle, so the extrapolation is biologically coherent, even without product-specific trials to confirm it.

Manufacturer clinical documentation does list the ankle among the most frequently treated sites alongside the knee and hip. That is useful context, but company-level records are not independent evidence, and conflating the two would misrepresent what is currently known.

The ankle is also one of the body's principal load-bearing joints, which makes the timing and degree of weight-bearing protection after any scaffold treatment a practical priority — a consideration that applies to injectable scaffold therapies in this joint generally.

The honest framing is this: ChondroFiller at the ankle has sound biological logic and is used in clinical practice, but it has not yet been tested in a peer-reviewed study. It sits closer to an evidence-informed emerging application than to an established indication, and individual suitability requires careful clinical assessment.

Shoulder cartilage defects: the largest evidence gap

No published clinical study — peer-reviewed or otherwise — has examined ChondroFiller specifically in the shoulder. The joint is mentioned in clinical documentation as a site for focal sports injuries, but a line in a manufacturer's FAQ is not evidence of an established indication, and it would be misleading to treat it as one.

That said, the absence of shoulder-specific data does not mean the biological logic is absent. ChondroFiller's mechanism — a structured collagen matrix that recruits the body's own repair cells into a cartilage defect — is not anatomically tied to any single joint. Younger, active patients with focal Grade III–IV lesions from sporting trauma represent broadly the same target profile in the shoulder as they do in the hip or wrist. The scaffold's requirements (a contained defect, preserved surrounding cartilage, no widespread joint degeneration) are patient-selection criteria, not joint-specific ones.

The shoulder does present distinct biomechanical conditions worth noting. Unlike the knee or hip, it bears relatively little axial load but faces high rotational demand — a different stress environment from the joints where evidence already exists. Whether those differences influence scaffold maturation or clinical outcomes has not been studied.

Of the four joints discussed here, the shoulder carries the thinnest evidential foundation. Any future use would sit firmly in the 'exploratory' category, and individual assessment would need to weigh the theoretical rationale against the current absence of clinical data.

How ChondroFiller works and why joint anatomy matters

At the point of placement, ChondroFiller is a liquid collagen gel that sets in situ inside a cartilage defect, forming a porous three-dimensional scaffold. It contains no cells of its own — it creates the structural conditions for the body's repair cells to migrate in and begin tissue formation.

A 2025 ex vivo osteochondral explant study recorded a 2.4-fold increase in DNA content within the scaffold by day 14, confirming active endogenous cell recruitment. That finding validates the biological mechanism but describes tissue-level activity rather than clinical cartilage regrowth — an important distinction for managing expectations.

What the same body of research also establishes is that the scaffold carries limited mechanical strength immediately after placement. A 2024 biomechanical study found that ChondroFiller cannot protect adjacent cartilage from damage under immediate cyclic loading, because the material remains mechanically unstable until the defect fills and the scaffold matures. Weight-bearing or high-demand movement in the early post-treatment period risks disrupting that process before repair cells have had time to establish themselves.

That consideration applies across all joints, but the practical stakes are highest where load is greatest. Both the ankle and the hip sustain forces several times body weight during normal activity, making a structured, supervised return to loading especially important in those sites.

Technique at delivery matters equally. Work in anatomically constrained joints has established that only a small volume of material is typically needed per defect, and that precisely flush filling is essential. Overfilling — rather than matching the defect level — produces fibrous rather than cartilage-type tissue. Accurate placement to the level of surrounding native cartilage, without excess, is what creates the conditions for the repair response the scaffold is designed to support.

Who is likely to benefit — and who may not

Across all joints where published evidence exists, certain patient characteristics consistently distinguish those more likely to benefit from those who are not.

Published data suggest outcomes are more favourable when the defect is focal — a discrete area of Grade III or IV damage rather than generalised joint-surface deterioration — and when the surrounding cartilage and underlying bone remain healthy. Defect size up to approximately 6 cm², contained borders, and well-preserved joint space are the core structural criteria. German epidemiological data on regenerative hip procedures found the typical patient profile centred on a mean age of around 27 years, which broadly reflects the focal-defect, OA-free picture that appears across the evidence base.

The contraindication established in the hip cohort — moderate-to-severe pre-existing osteoarthritis — is not unique to the hip. It reflects a consistent biological principle: diffuse joint degeneration shifts the tissue environment away from the conditions the scaffold needs to recruit and support repair cells. Patients with significant joint-space narrowing or widespread degeneration visible on imaging have consistently fared less well, regardless of joint site.

Age, defect type, OA grade, and joint-space status on imaging are therefore the practical self-screening filters — though none can be assessed reliably without professional input. A formal specialist assessment, including weight-bearing X-rays and MRI, is needed to grade OA severity, characterise defect size, and determine whether the surrounding tissue is suitable. Symptom pattern alone is not sufficient to establish candidacy.

Patients who want to understand whether their situation matches this clinical profile can complete a suitability assessment at amsk.co.uk.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Osteochondral lesions of the ankle: The current evidence supporting scaffold-based techniques and biological adjuncts. (2017). https://doi.org/10.1016/j.fas.2017.01.003 https://doi.org/10.1016/j.fas.2017.01.003
4. [4] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany: An Epidemiological Analysis from 2006 to 2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
7. [7] Arthroscopic Hip Transcapsular, Translabral Delivery of Orthobiologics for Single-Stage Cartilage Repair. (2025). https://doi.org/10.1016/j.eats.2025.103587 https://doi.org/10.1016/j.eats.2025.103587